Edwards Lifesciences Corporation (EW) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-25

Business type: Franchise

How it makes money

The SAPIEN transcatheter aortic valve platform drives 74% of net sales by allowing heart valve replacement without traditional open-heart surgery.

Revenue is primarily generated through the sale of bioprosthetic valves and repair systems to hospitals and clinicians. The business model centers on the SAPIEN family of valves, which are delivered via catheter while the heart is beating, reducing recovery times compared to traditional surgery.

Profitability is influenced by the product mix, specifically the adoption of premium technologies like the SAPIEN 3 Ultra RESILIA valve. Growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment also contributes to the mix as it scales globally.

What protects it: the moat

It defends its leading position with tissue technologies like RESILIA and 15 years of clinical trial data used to expand patient treatment guidelines.

The company maintains its competitive edge through a massive clinical evidence base, including studies of over 10,000 patients that support the use of its valves across diverse risk profiles. These studies drive the medical guidelines that determine which patients are eligible for transcatheter procedures.

Protection also stems from proprietary material science, such as the RESILIA tissue technology used to resist valve calcification. Additionally, field clinical specialists attend procedures to provide guidance, creating high switching costs by ensuring physician proficiency with the specific Edwards platform.

What growth costs

It reinvested 18% of its 2025 sales into research and development, focusing on clinical trials to prove the superiority of early intervention therapies.

Reinvestment is directed toward large-scale clinical trials such as EARLY TAVR and CLASP IIF, which are necessary to secure regulatory approvals for new indications like asymptomatic disease. These trials are costly and resource-intensive but essential for expanding the addressable patient population.

Beyond R&D, the company must fund a specialized direct sales force and field clinical specialists. These personnel are required to support the complex delivery of transcatheter therapies and to maintain relationships with hospital group purchasing organizations and integrated delivery networks.

What could damage it

Constrained hospital staffing and limited catheterization laboratory facilities can reduce procedure volumes because multiple products compete for the same specialized hospital resources.

The business relies on the capacity of healthcare systems to perform complex heart procedures. If hospitals face nursing shortages or limited availability of catheterization laboratories, they cannot utilize the company's valves regardless of clinical demand.

Earnings are also vulnerable to the 'cannibalization' of hospital resources, where the company's own newer therapies (like TMTT) compete with its established TAVR products for the same lab time and surgical staff, potentially capping the overall growth rate.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

More on EW

Other companies in Medical Devices